Evidence map›Paper›PMID 41819547›Full record

ArticleJournal for immunotherapy of cancer2026

Dual regulation of CXCR6

Zhang Xingming, Jianhua Wang, Mierxiati Abudurexiti, Leilei Du, Wei Zhang, Xudong Ni, Midie Xu, Xiaoyan Zhang, Min Zhang, Zhu Yao and 3 more

Abstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Zhang Xingming *Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China.
Jianhua WangCancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China jianhuaw2007@qq.com wangwenfeng1011@163.com jsmfdu@163.com xbian10@fudan.edu.cn.
Mierxiati Abudurexiti *Department of Urology, Pudong Gongli Hospital, Shanghai University of Medicine & Health Sciences, Shanghai, China.ORCID http://orcid.org/0000-0002-5909-6663
Leilei Du *Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID http://orcid.org/0000-0002-4163-0493
Wei ZhangCancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID http://orcid.org/0000-0003-0282-601X
Xudong NiCancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID http://orcid.org/0009-0005-3131-8964
Midie XuDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
Xiaoyan ZhangDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
Min ZhangPediatric Translational Medicine Institute and Pediatric Congenital Heart Disease Institute, Shanghai Children's Medical Center Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.ORCID http://orcid.org/0000-0001-7055-6790
Zhu YaoCancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China.
Xiaojie BianCancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China jianhuaw2007@qq.com wangwenfeng1011@163.com jsmfdu@163.com xbian10@fudan.edu.cn.
Shengming JinCancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China jianhuaw2007@qq.com wangwenfeng1011@163.com jsmfdu@163.com xbian10@fudan.edu.cn.ORCID http://orcid.org/0000-0001-8666-4606
Wenfeng WangCancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China jianhuaw2007@qq.com wangwenfeng1011@163.com jsmfdu@163.com xbian10@fudan.edu.cn.ORCID http://orcid.org/0000-0003-4083-4344

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProstate cancer (PCa) is widely recognized as an immunologically "cold" tumor, characterized by a paucity of effector T cells and a limited response to immune checkpoint blockade therapy. Although the chemokine receptor CXCR6 has been identified as a marker of highly cytotoxic CD8

methodsWe integrated newly generated and publicly available single-cell RNA sequencing data encompassing 90 651 cells from nine patients. Multicolor immunofluorescence and flow cytometry were performed on human PCa tissue specimens stratified by Gleason Score (GS). In parallel, syngeneic mouse models, bone marrow chimeras, and in vitro T-cell functional assays were employed to investigate the role, recruitment, and transcriptional regulation of CXCR6

resultsThe CXCR6

conclusionsThe CXCR6

Indexed as

CD8-Positive T-LymphocytesProstatic NeoplasmsReceptors, CXCR6AnimalsDisease ProgressionHumansMaleMiceT-Cell ExhaustionTumor MicroenvironmentCXCR6 protein, humanReceptors, CXCR6ImmunotherapyProstate CancerT cellTumor microenvironment - TME

Identifiers

PMID41819547
PMCPMC12983932

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.